Related Experiment Videos
[Use of immunosorption for selective decrease of lipoprotein (A) levels in patients with coronary atherosclerosis]
Insights
Lipoprotein (a) apheresis effectively and safely lowers high blood levels of this atherogenic lipoprotein. This treatment reduces coronary heart disease risk factors without affecting other vital lipoproteins.
Area of Science:
- Cardiovascular Science
- Lipid Metabolism
- Immunoadsorption Technology
Context:
- Elevated Lipoprotein (a) [L(a)] is a significant risk factor for coronary heart disease.
- Patients with high L(a) and coronary stenosis often have normal levels of other lipoproteins.
- Current treatment options for managing high L(a) are limited.
Purpose:
- To evaluate the efficacy and safety of L(a)-apheresis in patients with high L(a) and coronary stenosis.
- To assess the impact of L(a)-apheresis on L(a) levels and other plasma lipoproteins.
- To explore the potential of L(a)-apheresis as a therapeutic strategy for cardiovascular risk reduction.
Summary:
- A selective L(a)-apheresis procedure using an anti-L(a) immunosorbent was performed on three patients with high L(a) and coronary stenosis.
- Following treatment, L(a) levels decreased by 72% while other lipoproteins, including LDL, remained largely unchanged.
- The procedure demonstrated effectiveness and safety in reducing circulating L(a) concentrations.
Impact:
- L(a)-apheresis is a viable and safe method for lowering blood L(a) concentrations in at-risk individuals.
- This therapeutic approach may help mitigate the progression of coronary heart disease associated with high L(a).
- The study provides an in vivo model for further investigation into L(a) metabolism and targeted therapies.
Abstract:
Lipoprotein (a) [L(a)] is an atherogenic lipoprotein, its human plasma concentration correlates with the occurrence of coronary heart disease. The procedure for selectively removing L(a) with an anti-L(a) immunosorbent was performed to treat 3 patients who had high L(a), normal total cholesterol and other lipoprotein levels. All the patients had coronary stenosis as documented by angiography. After L(a)-apheresis, the level of L(a) decreased by 72%, while that of other plasma components, including low density lipoproteins virtually unchanged. Thus, the procedure of L(a)-apheresis is an effective and safe method for lowering human blood L(a) concentrations. In addition, this in vivo model allows information on L(a) metabolism to be obtained.